Focal adhesion kinase, usually called FAK, is a signaling protein that sits at the spots where cells physically grip their surrounding tissue. It acts as a relay station: when a cell attaches, detaches, or gets pushed and pulled by its environment, FAK converts those physical events into chemical signals that tell the cell whether to move, divide, survive, or die. That central role makes FAK relevant to a surprising range of biology, from wound healing and embryonic development to cancer spread, organ scarring, and even how certain bacteria survive inside your immune cells.
What FAK Actually Does Inside a Cell
Cells anchor themselves to the mesh of proteins around them (the extracellular matrix) through structures called focal adhesions. Think of these as molecular rivets connecting a cell’s internal skeleton to the outside world. FAK is embedded in those rivets. When a cell first latches on to a surface, FAK starts in a folded, inactive shape. One end of the protein, the FERM domain, physically blocks the part that would otherwise start sending signals. Activation requires the FERM domain to swing away, exposing a key site on the protein that can then be chemically tagged, a step called autophosphorylation.
That tag creates a docking site for another signaling protein called Src. Once Src arrives and binds, it adds more chemical tags to FAK, fully switching the protein on and unleashing a cascade of downstream signals that affect the cell’s skeleton, its survival pathways, and its ability to crawl from one place to another.
How does the FERM domain get out of the way in the first place? Research has shown that when FAK contacts a lipid membrane, the geometry of that interaction physically clashes with the folded shape, prying the protein open. In that membrane-bound state, the autophosphorylation site becomes exposed and multiple FAK molecules can cluster together, amplifying the signal.
The Cell’s Steering Wheel
One of FAK’s best-understood jobs is directing cell movement. For a cell to crawl in a particular direction, it has to form new adhesions at its leading edge, push forward, and then release its grip at the trailing edge. FAK coordinates all of these steps. It does so by cycling between activating and deactivating small molecular switches called Rho-family GTPases, which control where and when a cell extends a protrusion or retracts a tail.
FAK promotes the turnover of focal adhesions themselves, meaning it helps them form and then disassemble in a controlled rhythm. Without that turnover, cells get stuck. Src-dependent tagging of FAK is required for this process; experiments using a mutant form of FAK that cannot be tagged by Src showed that cells lose the ability to migrate and to remodel their internal skeleton properly.
The FAK–Src partnership also recruits a protein-cutting enzyme called calpain 2, which physically chops up adhesion components to allow disassembly. This mechanism links adhesion dynamics directly to cell survival signaling, meaning a cell that is crawling is simultaneously receiving “stay alive” signals through the same FAK pathway.
How Cells Feel Stiffness
Your tissues are not all the same firmness. Bone is rigid, brain tissue is soft, and a healing wound gradually stiffens as scar tissue forms. Cells sense these differences through mechanotransduction, the conversion of physical forces into biochemical signals, and FAK is one of the chief molecules responsible.
Focal adhesions sit at the boundary between outside and inside the cell, making them ideal checkpoints for mechanical information flowing in either direction. FAK responds to substrate stiffness, shear stress from fluid flow, and stretch forces from breathing or heartbeat. In the lining of blood vessels, for example, FAK mediates the response to the shearing force of blood rushing past, helping endothelial cells align with the direction of flow.
A particularly clear demonstration of FAK’s mechanosensing role comes from work on how stiffness drives cell division. A signaling chain running from FAK through an adaptor protein and then through the GTPase Rac converts the external information encoded by matrix stiffness into changes in internal cell stiffness and, ultimately, into the production of a protein called cyclin D1 that pushes cells into dividing. In other words, a stiffer environment literally tells the cell, via FAK, to proliferate.
This same mechanosensing logic extends to stem cells. The physical texture and stiffness of a surface can steer stem cells toward becoming bone, tendon, or fat cells, and FAK has been identified as a key regulator in that process. Experiments with tendon stem cells grown on silk films with a specific surface texture showed that the cells activated FAK and began expressing tendon-specific genes; blocking FAK shut that differentiation down.
FAK in Cancer
Given that FAK promotes cell survival, movement, and proliferation, it is not surprising that cancer cells often co-opt it. FAK is overexpressed or hyperactivated in many tumor types. It helps cancer cells do several things that normal cells should not: resist death signals when they detach from their home tissue (a resistance called anoikis resistance), invade through tissue barriers, and set up shop at distant sites during metastasis.
But FAK’s role in cancer goes beyond just keeping tumor cells alive and mobile. It also operates inside the nucleus, where it takes on a completely different character. Nuclear FAK promotes the degradation of the tumor-suppressor protein p53 by tagging it for disposal through the cell’s protein-recycling machinery. With less p53 around, cancer cells can keep dividing unchecked. Nuclear FAK also reduces inflammatory signaling by degrading the transcription factor GATA4 and suppressing certain immune-alerting molecules like IL-33. The net effect is a tumor that grows faster and hides more effectively from the immune system.
The distinction between active and inactive FAK matters here. When FAK is active in the nucleus, it binds transcription factors and changes gene expression directly. When it is inactive, it teams up with protein-disposal enzymes called E3 ligases to accelerate the turnover of transcription factors. Both modes serve the tumor’s interests.
Reshaping the Tumor’s Neighborhood
Some of the most striking cancer research on FAK focuses not on the tumor cells themselves but on the tissue surrounding them, the tumor microenvironment. In pancreatic ductal adenocarcinoma, one of the deadliest cancers, researchers found that hyperactivated FAK in tumor cells drove the formation of a dense, fibrous barrier around the tumor. That fibrotic shell did two things: it physically blocked immune cells from getting in, and it attracted immunosuppressive cells that further dampened the anti-tumor response. The result was a tumor with very few cancer-killing CD8+ T cells inside it.
When FAK activity was blocked in mouse models, the fibrosis dropped, the immunosuppressive cells retreated, and T cells flooded in. The tumors, which had previously ignored checkpoint immunotherapy drugs entirely, became responsive to them. This finding was significant because pancreatic cancer is notorious for being resistant to immunotherapy, and FAK inhibition appeared to crack that resistance open.
Similar results have appeared in a specific subtype of lung adenocarcinoma driven by mutations in both KRAS and LKB1. These tumors are considered “immune-cold,” meaning they have very little immune cell infiltration. FAK inhibition in this context remodeled the microenvironment by suppressing activated cancer-associated fibroblasts, reducing collagen buildup, and allowing CD8+ T cells, dendritic cells, and anti-tumor macrophages to infiltrate the tumor, effectively converting a cold tumor into a hot one.
Lung Fibrosis and Other Non-Cancer Diseases
The fibrosis connection extends well beyond cancer. In idiopathic pulmonary fibrosis, a progressive lung disease where healthy tissue is replaced by stiff scar tissue, FAK expression and activity are elevated in the clusters of scar-forming cells called myofibroblast foci. Myofibroblasts are the workhorses of scarring: they contract tissue, lay down collagen, and resist dying when their job should be done. FAK is required for normal fibroblasts to transform into these myofibroblasts in the first place.
In mouse models of lung fibrosis, pharmacological or genetic inactivation of FAK markedly reduced scarring. The mechanism runs through a signaling branch involving a stress-activated enzyme called JNK: pro-fibrotic signals from growth factors converge on FAK, which activates JNK through integrin signaling, which in turn switches on the genes that drive the myofibroblast program. Fibroblasts engineered to lack FAK simply could not acquire the profibrotic character even when bathed in the growth factor TGF-β1, which is one of the strongest known triggers of scarring.
Beyond the lungs, FAK has roles in cardiovascular health. It appears to be involved in the thickening of heart muscle cells during cardiac hypertrophy and in cell death triggered by cycles of low oxygen followed by re-oxygenation, the kind of injury that occurs during a heart attack and subsequent restoration of blood flow.
FAK and Metabolic Health
A less intuitive corner of FAK biology involves metabolism. Fat tissue is not just a passive energy store; it actively regulates insulin sensitivity across the whole body. When researchers deleted FAK specifically in fat cells of mice, the animals developed elevated fasting blood sugar and insulin resistance by just 12 weeks of age. Both male and female mice were affected. Their insulin levels climbed, their pancreatic beta cells expanded to compensate, and their response to injected insulin was blunted, all without changes in glucose tolerance testing.
More recently, work in primary human and mouse fat cells has shown that FAK inhibition cuts glucose uptake by roughly half, both in the resting state and after insulin stimulation. FAK appears to orchestrate the movement of the glucose transporter GLUT4 to the cell surface, the step that allows fat cells to absorb sugar from the blood. Without FAK activity, GLUT4 trafficking stalls because the internal cytoskeletal rearrangements it depends on do not happen properly.
Broader reviews have linked dysregulation of focal adhesion proteins, including FAK, to several features of metabolic syndrome: impaired fat cell expansion, liver fibrosis, and cardiovascular dysfunction. The emerging picture is that FAK’s mechanosensing role in fat tissue helps cells adapt to changing mechanical loads as adipose tissue expands or contracts, and when that sensing breaks down, metabolic consequences follow.
When Pathogens Hijack FAK
Several disease-causing microorganisms have evolved strategies to manipulate FAK signaling for their own benefit. The logic is elegant from the pathogen’s perspective: focal adhesions are the cell’s entry points, so hijacking the molecules that control them is a direct route to getting inside and staying there.
Salmonella provides one of the clearest examples. After invading a macrophage (an immune cell whose job is to destroy bacteria), Salmonella uses a specialized secretion system to recruit FAK to the surface of the compartment it hides in. That FAK recruitment amplifies survival signaling through a chain of molecules that ultimately suppresses autophagy, the cell’s internal cleanup process that would otherwise digest the bacteria. In macrophages engineered to lack FAK, autophagic capture of the bacteria increased and bacterial survival dropped.
The parasite Toxoplasma gondii uses a related trick. Upon infecting a mammalian cell, it activates a signaling chain that runs from FAK through Src and ultimately to a transcription factor called STAT3, which suppresses the host cell’s autophagy response. By keeping this pathway active, the parasite avoids being targeted for destruction. These examples illustrate that FAK is not just a player in chronic disease; it is a vulnerability that infectious agents have learned to exploit.
Developing Drugs That Target FAK
Given FAK’s involvement in cancer progression, fibrosis, and immune evasion, pharmaceutical interest has been substantial. The first generation of FAK inhibitors were designed to block the protein’s enzymatic activity by competing with ATP, the molecule FAK uses to tag its targets. These compounds bind directly to the kinase domain and shut down multiple downstream signaling pathways. Several, including defactinib, have entered clinical trials.
The clinical results, though, have been mixed. FAK inhibitors showed promising performance in preclinical work and early-stage trials, but the protein’s dual nature created a problem. FAK does not just act as an enzyme; it also serves as a physical scaffold, gathering other signaling proteins into complexes. Traditional kinase inhibitors block the enzymatic activity but leave the scaffold intact, so some of FAK’s tumor-promoting functions persist even when its kinase is switched off.
This realization spurred interest in a newer approach: targeted protein degradation. Rather than just blocking FAK, degrader molecules called PROTACs (proteolysis-targeting chimeras) hijack the cell’s own protein-disposal machinery to eliminate FAK entirely. An early FAK PROTAC outperformed defactinib in blocking both FAK activation and FAK-dependent cell migration and invasion, precisely because removing the whole protein eliminates both the kinase and the scaffolding functions.
More recent work has refined this approach further. One degrader compound demonstrated potent and selective FAK destruction and, critically, upregulated genes involved in antigen processing and presentation on tumor cells. By removing FAK, the compound increased the surface display of molecules that help immune cells recognize tumors, thereby enhancing the activation of cancer-killing CD8+ T cells. This effect was specifically tied to FAK’s non-enzymatic functions, something a kinase inhibitor alone could not achieve.
Not everything about PROTACs is straightforward, however. A direct comparison of FAK-targeting strategies found that while the kinase inhibitor defactinib achieved low inhibitory concentrations regardless of FAK levels, a PROTAC compound showed minimal effects in some settings, with inhibitory concentrations sometimes exceeding practical thresholds despite successfully destroying the protein. The field is still working out when degradation is better than inhibition and whether the two strategies might complement each other.
FAK in Nerve Growth and Brain Wiring
FAK’s influence on cell movement extends into the nervous system. During brain development, growing nerve fibers navigate toward their targets by extending a structure called a growth cone at their tip, a hand-like protrusion that feels its way through tissue by forming and releasing tiny adhesion points. FAK functions downstream of guidance cues like brain-derived neurotrophic factor and the matrix protein laminin to control the dynamics of those adhesion points. When FAK function is knocked down in nerve cells, growth cones lose the ability to accelerate adhesion turnover in response to guidance signals, and the directed turning that guides axons to their correct destinations fails. This is one of the first demonstrations that the small adhesion contacts at a growth cone’s tips are regulated asymmetrically during turning, with FAK playing a central role in that asymmetry.
The structural basis for FAK’s versatility across such different cell types traces to its FERM domain, which belongs to an ancient protein family found in organisms ranging from single-celled eukaryotes to humans. This domain is shared with other important signaling proteins and has a conserved ability to bind membrane lipids and interact with transmembrane receptors. Its evolutionary persistence suggests that the ability to link cell-surface adhesion events to internal signaling networks is one of the oldest and most fundamental capabilities in cell biology, and FAK is one of its most elaborate expressions.